Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study)
- PMID: 15194022
- DOI: 10.1016/j.amjcard.2004.03.007
Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study)
Abstract
Recognition of the frequency with which hypertrophic cardiomyopathy (HC) occurs in the general population is critical to understanding its demographics and public health implications. However, few data are available for estimating HC prevalence in large populations of different age strata and ethnic or racial groups. The Strong Heart Study is a prospective, population-based epidemiologic survey of cardiovascular disease in residents of 13 geographically diverse American Indian communities. The study population was comprised of 3,501 subjects with echocardiograms performed in 1993 and 1995 to determine the prevalence of HC in middle-aged and older adult populations. Evidence of the HC phenotype was present in 8 previously undiagnosed patients (0.23%; 2 of 1,000) based on a left ventricular (LV) wall thickness >/=15 mm and a nondilated cavity that was not associated with another cardiac disease and was sufficient to produce the magnitude of hypertrophy evident. Ages were 51 to 77 years (mean 64 +/- 9). Four subjects were men and 4 were women, with prevalences by gender of 0.3% (3 of 1,000) and 0.18% (1.8 of 1,000), respectively. Maximum LV thicknesses were 19 to 29 mm (mean 21 +/- 3). Two subjects had mitral valve systolic anterior motion, which was sufficient to produce LV outflow obstruction at rest in 1 patient. Different electrocardiographic abnormalities were present in 5 subjects. In conclusion, clinically unrecognized HC was present in 1:500 of an aging American Indian cohort. This prevalence was similar to that reported in other general populations comprised of younger subjects of other races, offering evidence that HC is a relatively common genetic disease with widespread occurrence within the United States.
Similar articles
-
Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States.Am J Cardiol. 2003 Nov 15;92(10):1183-6. doi: 10.1016/j.amjcard.2003.07.027. Am J Cardiol. 2003. PMID: 14609593
-
Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy.Am J Cardiol. 2005 Jul 15;96(2):270-5. doi: 10.1016/j.amjcard.2005.03.058. Am J Cardiol. 2005. PMID: 16018856
-
Onset of apical hypertrophic cardiomyopathy in adulthood.Am J Cardiol. 2011 Dec 15;108(12):1783-7. doi: 10.1016/j.amjcard.2011.07.048. Epub 2011 Sep 28. Am J Cardiol. 2011. PMID: 21958740
-
Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States.Am J Cardiol. 2016 May 15;117(10):1651-1654. doi: 10.1016/j.amjcard.2016.02.044. Epub 2016 Mar 2. Am J Cardiol. 2016. PMID: 27006153
-
Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study.Am J Cardiol. 1994 Mar 15;73(8):577-80. doi: 10.1016/0002-9149(94)90337-9. Am J Cardiol. 1994. PMID: 8147304
Cited by
-
Looking for hypertrophic cardiomyopathy in the community: why is it important?J Cardiovasc Transl Res. 2009 Dec;2(4):392-7. doi: 10.1007/s12265-009-9135-4. Epub 2009 Oct 20. J Cardiovasc Transl Res. 2009. PMID: 20559997 Review.
-
Cardiomyopathies: An Overview.Int J Mol Sci. 2021 Jul 19;22(14):7722. doi: 10.3390/ijms22147722. Int J Mol Sci. 2021. PMID: 34299342 Free PMC article. Review.
-
Screening UFMylation-associated genes in heart tissues of Ufm1-transgenic mice.BMC Cardiovasc Disord. 2023 Nov 18;23(1):567. doi: 10.1186/s12872-023-03563-7. BMC Cardiovasc Disord. 2023. PMID: 37980507 Free PMC article.
-
Model for classification of heart failure severity in patients with hypertrophic cardiomyopathy using a deep neural network algorithm with a 12-lead electrocardiogram.Open Heart. 2023 Dec 6;10(2):e002414. doi: 10.1136/openhrt-2023-002414. Open Heart. 2023. PMID: 38056911 Free PMC article.
-
Austrian consensus statement on the diagnosis and management of hypertrophic cardiomyopathy.Wien Klin Wochenschr. 2024 Oct;136(Suppl 15):571-597. doi: 10.1007/s00508-024-02442-1. Epub 2024 Oct 1. Wien Klin Wochenschr. 2024. PMID: 39352517 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources